Interestingly, our clinical [19] and preclinical [23] experience of IL13Rα2-CAR T cells against GBM demonstrated that a strong CAR T antitumor response is associated with the activation of the host immune cells, suggesting that the host immune cells may play an important role in a successful CAR T therapy. This evidence concerns the gene IL13RA2 and glioblastoma.